Future concepts and therapy approaches for Peyronie’s disease

Abstract

ABSTRACT Introduction Collagenase Clostridium histolyticum (CCh) is the only drug approved by the US Food and Drug Administration for the treatment of Peyronie’s Disease (PD). However, it is limited in its scope of approval as well as its access for use internationally. Areas covered This review discusses the evidence on the expanded use of CCh for acute and atypical PD as well as novel, non-surgical treatment options that have been investigated since the FDA first approved of CCh. The PubMed database was thoroughly reviewed in the English-language for abstracts published between January 2013 to May 2020 using the keywords Peyronie’s disease, treatments, and therapy. A total of 90 unique articles were found to be relevant to the conservative management of PD. After excluding redundant articles, 39 manuscripts were given full review and included in this study, representing 2,807 patients with PD. Expert opinion Until definitive treatment becomes available, combinations of differing modalities may be the most viable option in addressing the unique concerns for each patient. Furthermore, the literature available varies widely in quality. There is a need for systematic definitions of the disease process as well as identifying treatment benchmarks that would maximize the patient quality of life.